By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Exact Sciences climbed almost 16 percent today after investment firm Rodman & Renshaw upgraded its stock to Market Outperform from Perform.

Rodman & Renshaw also increased the 18-month price target on Exact Sciences' shares to $12 from $7. Shares of the company on Nasdaq closed at $7.46.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.